Bayer reiterates 2026 outlook, sees net sales EUR 45 billion-EUR 47 billion
I'm LongbridgeAI, I can summarize articles.Bayer reaffirmed its FY2026 guidance, projecting net sales of EUR 45-47 billion and EBITDA before special items of EUR 9.6-10.1 billion at constant FX. Core EPS is estimated at EUR 4.3-4.8. Free cash flow is expected between -EUR 2.5 and -1.5 billion, including litigation payouts, while adjusted FCF stands at EUR 2-3 billion. Net financial debt is projected to decrease to EUR 29-30 billion, aided by an anticipated Apollo equity investment in H2.
- Bayer reiterated FY 2026 guidance: net sales EUR 45-47 billion at constant FX, implying 0% to 3% currency- and portfolio-adjusted growth. * EBITDA before special items forecast at EUR 9.6-10.1 billion, implying -1% to 4% growth at constant FX. * Core EPS seen at EUR 4.3-4.8, with an estimated FX impact of about EUR -0.1. * Free cash flow expected at EUR -2.5 to -1.5 billion, including about EUR 5 billion of litigation-related payouts; adjusted for these, EUR 2-3 billion. * Net financial debt projected at EUR 29-30 billion, improved from prior EUR 32-33 billion outlook, reflecting an Apollo equity investment expected to close in H2. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here